Dynamics-Adapted Radiotherapy Dose (DARD) for Head and Neck Cancer Radiotherapy Dose Personalization
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Data
2.2. Mathematical Model
2.3. Model Calibration and Fitting
2.4. Dose Personalization Framework
2.5. Dose Personalization In Silico Trial Design
3. Results
3.1. Model Fitting
3.2. Personalized Dynamics-Adapted Radiation Therapy Dose (DDARD)
3.3. Dose Personalization within Restricted Dose Range
4. Discussion
5. Patents
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA A Cancer J. Clin. 2021, 71, 7–33. [Google Scholar] [CrossRef] [PubMed]
- Chaturvedi, A.K.; Engels, E.A.; Pfeiffer, R.M.; Hernandez, B.Y.; Xiao, W.; Kim, E.; Jiang, B.; Goodman, M.T.; Sibug-Saber, M.; Cozen, W.; et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 2011, 29, 4294–4301. [Google Scholar] [CrossRef] [PubMed]
- Pfister, D.G.; Spencer, S.; Adelstein, D.; Adkins, D.; Anzai, Y.; Brizel, D.M.; Bruce, J.Y.; Busse, P.M.; Caudell, J.J.; Cmelak, A.J.; et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 2020, 18, 873–898. [Google Scholar] [CrossRef] [PubMed]
- Ko, C.; Citrin, D. Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. Oral Dis. 2009, 15, 121–132. [Google Scholar] [CrossRef] [Green Version]
- Tursz, T.; Andre, F.; Lazar, V.; Lacroix, L.; Soria, J.-C. Implications of personalized medicine—perspective from a cancer center. Nat. Rev. Clin. Oncol. 2011, 8, 177–183. [Google Scholar] [CrossRef]
- Patel, R.R.; Ludmir, E.B.; Augustyn, A.; Zaorsky, N.G.; Lehrer, E.J.; Ryali, R.; Trifiletti, D.M.; Adeberg, S.; Amini, A.; Verma, V. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials. Oral Oncol. 2020, 103, 104608. [Google Scholar] [CrossRef]
- Wirth, L.J.; Burtness, B.; Nathan, C.-A.O.; Grégoire, V.; Richmon, J. Point/counterpoint: Do we de-escalate treatment of HPV-associated oropharynx cancer now? and how? Am. Soc. Clin. Oncol. Educ. B 2019, 39, 364–372. [Google Scholar] [CrossRef]
- Mirghani, H.; Blanchard, P. Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? Clin. Transl. Radiat. Oncol. 2018, 8, 4–11. [Google Scholar] [CrossRef] [Green Version]
- Riaz, N.; Sherman, E.; Pei, X.; Schöder, H.; Grkovski, M.; Paudyal, R.; Katabi, N.; Selenica, P.; Yamaguchi, T.N.; Ma, D.; et al. Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. JNCI J. Natl. Cancer Inst. 2021, 113, 742–751. [Google Scholar] [CrossRef]
- Mellon, E.; Yue, B.; Strom, T.S.; Torres-Roca, J.F.; Fulp, W.J.; Scott, J.G.; Moros, E.; Ahmed, K.; Mihaylov, I.; Caudell, J.J.; et al. A genome-based model for adjusting radiotherapy dose (GARD): A retrospective, cohort-based study. Lancet Oncol. 2016, 18, 202–211. [Google Scholar] [CrossRef]
- Eschrich, S.A.; Pramana, J.; Zhang, H.; Zhao, H.; Boulware, D.; Lee, J.H.; Bloom, G.; Rocha-Lima, C.; Kelley, S.; Calvin, D.P.; et al. A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After Chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75, 489–496. [Google Scholar] [CrossRef] [Green Version]
- Enderling, H.; Alfonso, J.C.L.; Moros, E.; Caudell, J.J.; Harrison, L.B. Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy. Trends Cancer 2019, 5, 467–474. [Google Scholar] [CrossRef]
- Aherne, N.J.; Dhawan, A.; Scott, J.G.; Enderling, H. Mathematical oncology and it’s application in non melanoma skin cancer--A primer for radiation oncology professionals. Oral Oncol. 2020, 103, 104473. [Google Scholar] [CrossRef]
- Caudell, J.J.; Torres-Roca, J.F.; Gillies, R.J.; Enderling, H.; Kim, S.; Rishi, A.; Moros, E.G.; Harrison, L.B. The future of personalised radiotherapy for head and neck cancer. Lancet Oncol. 2017, 18, e266–e273. [Google Scholar] [CrossRef]
- Prokopiou, S.; Moros, E.G.; Poleszczuk, J.; Caudell, J.; Torres-Roca, J.F.; Latifi, K.; Lee, J.K.; Myerson, R.; Harrison, L.B.; Enderling, H. A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation. Radiat. Oncol. 2015, 10, 159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sunassee, E.D.; Tan, D.; Ji, N.; Brady, R.; Moros, E.G.; Caudell, J.J.; Yartsev, S.; Enderling, H. Proliferation Saturation Index in an adaptive Bayesian approach to predict patient-specific radiotherapy responses. Int. J. Radiat. Biol. 2019, 95, 1421–1426. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zahid, M.U.; Mohamed, A.S.R.; Latifi, K.; Rishi, A.; Harrison, L.B.; Fuller, C.D.; Moros, E.G.; Caudell, J.J.; Enderling, H. Proliferation Saturation Index to Characterize Response to Radiation Therapy and Evaluate Altered Fractionation in Head and Neck Cancer. Appl. Radiat. Oncol. 2021, 10, 32–39. [Google Scholar]
- Zahid, M.U.; Mohsin, N.; Mohamed, A.S.R.; Caudell, J.J.; Harrison, L.B.; Fuller, C.D.; Moros, E.G.; Enderling, H. Forecasting Individual Patient Response to Radiotherapy in Head and Neck Cancer with a Dynamic Carrying Capacity Model. Int. J. Radiat. Oncol. Biol. Phys. 2021, 111, 693–704. [Google Scholar] [CrossRef] [PubMed]
- Byun, D.J.; Tam, M.M.; Jacobson, A.S.; Persky, M.S.; Tran, T.T.; Givi, B.; DeLacure, M.D.; Li, Z.; Harrison, L.B.; Hu, K.S. Prognostic potential of mid-treatment nodal response in oropharyngeal squamous cell carcinoma. Head Neck 2020, 43, 173–181. [Google Scholar] [CrossRef]
- Moons, K.G.M.; Altman, D.G.; Reitsma, J.B.; Ioannidis, J.P.A.; Macaskill, P.; Steyerberg, E.W.; Vickers, A.J.; Ransohoff, D.F.; Collins, G.S. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and elaboration. Ann. Intern. Med. 2015, 162, W1–W73. [Google Scholar] [CrossRef] [Green Version]
- Beitler, J.J.; Zhang, Q.; Fu, K.K.; Trotti, A.; Spencer, S.A.; Jones, C.U.; Garden, A.S.; Shenouda, G.; Harris, J.; Ang, K.K. Final results of local-regional control and late toxicity of RTOG 9003: A randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2014, 89, 13–20. [Google Scholar] [CrossRef] [Green Version]
- Marur, S.; Li, S.; Cmelak, A.J.; Gillison, M.L.; Zhao, W.J.; Ferris, R.L.; Westra, W.H.; Gilbert, J.; Bauman, J.E.; Wagner, L.I.; et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx—ECOG-ACRIN Cancer Research Group. J. Clin. Oncol. 2017, 35, 490–497. [Google Scholar] [CrossRef] [PubMed]
- Chen, A.M.; Felix, C.; Wang, P.-C.; Hsu, S.; Basehart, V.; Garst, J.; Beron, P.; Wong, D.; Rosove, M.H.; Rao, S.; et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm, phase 2 study. Lancet Oncol. 2017, 18, 803–811. [Google Scholar] [CrossRef] [Green Version]
- Levendag, P.C.; Teguh, D.N.; Voet, P.; van der Est, H.; Noever, I.; de Kruijf, W.J.M.; Kolkman-Deurloo, I.K.; Prevost, J.B.; Poll, J.; Schmitz, P.I.M.; et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: A dose-effect relationship. Radiother. Oncol. 2007, 85, 64–73. [Google Scholar] [CrossRef]
- Brady, R.; Enderling, H. Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to. Bull. Math. Biol. 2019, 81, 3722–3731. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Mean Escalation (Gy) | 0 | 38.9 | 12.4 |
Mean De-Escalation (Gy) | 0 | 32.0 | 10.7 |
LRC Rate | 84.6% | 100% | 94.9% 1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zahid, M.U.; Mohamed, A.S.R.; Caudell, J.J.; Harrison, L.B.; Fuller, C.D.; Moros, E.G.; Enderling, H. Dynamics-Adapted Radiotherapy Dose (DARD) for Head and Neck Cancer Radiotherapy Dose Personalization. J. Pers. Med. 2021, 11, 1124. https://doi.org/10.3390/jpm11111124
Zahid MU, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Dynamics-Adapted Radiotherapy Dose (DARD) for Head and Neck Cancer Radiotherapy Dose Personalization. Journal of Personalized Medicine. 2021; 11(11):1124. https://doi.org/10.3390/jpm11111124
Chicago/Turabian StyleZahid, Mohammad U., Abdallah S. R. Mohamed, Jimmy J. Caudell, Louis B. Harrison, Clifton D. Fuller, Eduardo G. Moros, and Heiko Enderling. 2021. "Dynamics-Adapted Radiotherapy Dose (DARD) for Head and Neck Cancer Radiotherapy Dose Personalization" Journal of Personalized Medicine 11, no. 11: 1124. https://doi.org/10.3390/jpm11111124